前列腺癌治療市場規模、佔有率和成長分析（按藥物類型、通路和地區分類）：產業預測（2026-2033 年）

預計到 2024 年，攝護腺癌治療市場規模將達到 130.6 億美元，到 2025 年將達到 140.9 億美元，到 2033 年將達到 258.8 億美元，預測期（2026-2033 年）的複合年成長率為 7.9%。

全球前列腺癌治療市場呈現出蓬勃發展且不斷演變的態勢，其主要驅動力是男性前列腺癌發生率的上升。人口老化、公眾意識的提高以及早期診斷技術的進步推動了這一成長，進而促進了創新治療方法的研發。然而，高昂的治療費用和潛在的副作用等挑戰可能會阻礙這些療法的廣泛應用。關鍵的市場促進因素包括研發投入、複雜在研藥物的推出以及各階段癌症患者對荷爾蒙療法日益成長的需求。此外，新興經濟體也蘊藏著巨大的成長機遇，但發展中地區治療週期較長等挑戰可能會影響市場擴張。個人化治療方案和標靶化藥物的改進為改善患者預後提供了更多機會。

攝護腺癌治療促進因素

前列腺癌發生率的不斷上升與多種因素相關，尤其是全球人口老化程度的加深。隨著人們對該疾病認知的提高和診斷技術的進步，早期發現前列腺癌的可能性也隨之增加。這種認知的提高，加上強力的篩檢措施，導致報告病例數顯著增加。因此，開發有效的治療策略和創新治療方法已成為當務之急。這些因素共同推動著前列腺癌治療領域的發展與擴張。

限制前列腺癌治療市場的因素

全球前列腺癌治療市場面臨許多挑戰，尤其是標靶治療和免疫療法的高昂費用。儘管這些先進的治療方案在改善患者預後方面展現出巨大潛力，但其成本效益仍是一大障礙。包括免疫抑制藥物在內的治療費用對患者和醫療系統而言都可能造成沉重的經濟負擔，限制了患者照護的療法的機會。因此，許多患者難以負擔醫療費用，凸顯了消除經濟障礙的緊迫性，以確保患者能夠公平地獲得這些重要且可能挽救生命的治療方法。

攝護腺癌治療市場趨勢

前列腺癌治療市場正經歷著向個人化醫療的重大轉變，強調根據每位患者的基因和分子特徵量身定做治療方案。基因組分析技術的應用使醫療服務提供者能夠識別癌細胞內的特定生物標記和基因突變，從而顯著提高治療的精確度。這種方法不僅最佳化了治療效果，還減少了不必要的干涉措施及其相關副作用，最終改善了患者的預後。諸如前列腺健康指數 (PHI) 和 Oncotype DX 基因組前列腺評分等生化檢測在識別標標靶治療（例如針對特定 DNA 修復通路突變的奧拉帕尼和盧卡帕尼）的候選患者方面正變得越來越重要。這一趨勢表明，腫瘤治療策略中對以患者為中心的創新方法的需求日益成長。

目錄

介紹

• 分析目的
• 市場覆蓋範圍
• 定義

分析方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況及展望
• 供需趨勢分析
• 按細分市場進行機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特五力分析

關鍵市場考量因素

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場魅力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管環境
• 案例研究
• 技術進步

全球前列腺癌治療市場規模及按藥物類型分類的複合年成長率（2026-2033 年）

• 前列腺癌荷爾蒙療法治療
  • 黃體激素釋放激素（LHRH）拮抗劑
  • Zytiga
  • 戈納克斯
  • 黃體激素釋放激素（LHRH）促效劑
  • 亮丙瑞林
  • Zoladex
  • 埃利加德
  • 癸肽
  • 凡塔斯
  • 其他
  • 抗雄性激素療法
  • 埃斯坦迪
  • 卡索德克斯
• 攝護腺癌化療
  • Taxotere
  • Jevtana
• 前列腺癌免疫療法
  • Provenge
• 標靶治療
  • 佐菲戈
• 其他前列腺癌治療方法

全球前列腺癌治療市場規模及按分銷管道分類的複合年成長率（2026-2033 年）

• 醫院藥房
• 藥局和零售藥房
• 網路藥房

全球前列腺癌治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭格局

• 前五大公司對比
• 主要企業市場定位（2025 年）
• 主要企業採取的策略
• 近期市場趨勢
• 主要企業市佔率（2025 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 年比營收比較（2023-2025）

主要企業簡介

• 艾伯維公司（美國）
• 安進公司（美國）
• 葛蘭素史克有限公司（英國）
• 默克集團（德國）
• Viatris公司（美國）
• 諾華公司（瑞士）
• 輝瑞公司（美國）
• 武田藥品工業株式會社（日本）
• Exelixis Inc.（美國）
• IBSA Pharma（IBSA 集團）（瑞士）
• 雅培實驗室（美國）
• Alvogen Iceland ehf（冰島）
• 費森尤斯股份公司（德國）
• 傑羅姆史蒂文斯製藥公司（美國）
• Lannett Co. Inc.（美國）
• 魯賓有限公司（印度）
• Mayne Pharma Group Ltd.（澳洲）
• Piramal Enterprises Ltd.（印度）
• RLC Labs Inc.（美國）
• 太陽製藥工業有限公司（印度）

結論與建議

Prostate Cancer Treatment Market size was valued at USD 13.06 Billion in 2024 and is poised to grow from USD 14.09 Billion in 2025 to USD 25.88 Billion by 2033, growing at a CAGR of 7.9% during the forecast period (2026-2033).

The global prostate cancer treatment market reflects a vibrant and evolving landscape driven by rising incidences of prostate cancer among men. This growth is fueled by an increasing aging population, heightened awareness, and advancements in early diagnosis, leading to the development of innovative treatments and therapies. Nevertheless, challenges such as high treatment costs and the potential side effects associated with therapies may hinder broader adoption. Key market drivers include research and development investments, the introduction of complex pipeline drugs, and the rising demand for hormonal therapies in various cancer stages. Additionally, emerging economies offer significant growth opportunities, although challenges like prolonged healing periods in underdeveloped regions can impact market expansion. Personalized treatment approaches and improved drug targeting present further opportunities for enhancing patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Prostate Cancer Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Prostate Cancer Treatment Market Segments Analysis

Global Prostate Cancer Treatment Market is segmented by Drug Type, Distribution Channel and region. Based on Drug Type, the market is segmented into Hormonal Prostate Cancer Therapy, Prostate Cancer Chemotherapy, Prostate Cancer Immunotherapy, Prostate Cancer Targeted Therapy and Others Prostate Cancer. Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Prostate Cancer Treatment Market

The growing prevalence of prostate cancer can be linked to various elements, notably the increasing proportion of elderly individuals worldwide. As more people become aware of the disease and diagnostic techniques advance, the likelihood of identifying prostate cancer at early stages rises. This heightened awareness, combined with robust screening initiatives, has resulted in a notable uptick in reported cases. Consequently, this situation highlights the pressing need for effective treatment strategies and the development of innovative therapeutic options within the market. The confluence of these factors serves to stimulate the progression and expansion of the prostate cancer treatment landscape.

Restraints in the Prostate Cancer Treatment Market

The global prostate cancer treatment market encounters notable challenges, particularly regarding the high costs associated with targeted therapies and immunotherapies. While these advanced treatment options demonstrate considerable potential in enhancing patient outcomes, their affordability poses a significant obstacle. The financial burden of therapies, including immunosuppressants, can be overwhelming for both patients and healthcare systems. This results in limited access to alternative treatments that could significantly improve patient care. Consequently, many individuals face difficulties in managing their healthcare expenses, highlighting the urgent need to address financial barriers to ensure equitable access to these critical, and potentially life-saving, therapies for prostate cancer.

Market Trends of the Prostate Cancer Treatment Market

The prostate cancer treatment market is witnessing a significant shift towards personalized medicine, emphasizing tailored therapies that align with individual genetic and molecular profiles. The application of genomic analysis enables healthcare providers to identify specific biomarkers and genetic mutations within cancer cells, significantly enhancing treatment precision. This approach not only optimizes therapeutic efficacy but also mitigates unnecessary interventions and associated side effects, ultimately improving patient outcomes. Biochemical tests, such as the Prostate Health Index (PHI) and Oncotype DX Genomic Prostate Score, are gaining prominence in identifying candidates for targeted therapies, such as olaparib and rucaparib, which address specific DNA repair pathway alterations. This trend underscores the growing demand for innovative, patient-centric approaches in oncological treatment strategies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Prostate Cancer Treatment Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Hormonal Prostate Cancer Therapy
  • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
  • Zytiga
  • Gonax
  • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
  • Lupron
  • Zoladex
  • Eligard
  • Decapeptyl
  • Vantas
  • Others
  • Anti-Androgen
  • Xtandi
  • Casodex
• Prostate Cancer Chemotherapy
  • Taxotere
  • Jevtana
• Prostate Cancer Immunotherapy
  • Provenge
• Prostate Cancer Targeted Therapy
  • Xofigo
• Others Prostate Cancer

Global Prostate Cancer Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospitals Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Global Prostate Cancer Treatment Market Size & CAGR (2026-2033)

• North America (Drug Type, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IBSA Pharma (IBSA Group) (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alvogen Iceland ehf (Iceland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jerome Stevens Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lannett Co. Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayne Pharma Group Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Enterprises Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RLC Labs Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations